Colleen Silk/LinkedIn
Nov 4, 2025, 08:22
Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”Rare diseases remind us that science must never overlook the few.
Hemophilia B with inhibitors affects only a small number of people, yet its impact is profound.
We are proud to have been recognized as a finalist for the 2025 Prix Galien US Award for Best Orphan/Rare Disease Product.
Novo Nordisk believes that every person—no matter how rare their condition—deserves the best that science can offer.
We’re proud of this recognition and grateful to the Prix Galien Foundation for honoring innovation that makes a real difference.”
More winner stories featured in Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026